Ads
related to: lymphoblastic leukemia treatment- Safety & Side Effects
Read Important Safety And Possible
Side Effects Information.
- Take The Quiz
Find Out If This Treatment Option
Is Right For You
- Safety & Side Effects
Search results
Results from the WOW.Com Content Network
Treatment usually also includes intrathecal chemotherapy since systemic chemotherapy can have limited penetration into the central nervous system and the central nervous system is a common site for relapse of acute lymphoblastic leukemia. [12] [13] Treatment can also include radiation therapy if spread to the brain has occurred. [2]
Obecabtagene autoleucel, sold under the brand name Aucatzyl, is an anti-cancer medication used for the treatment of acute lymphoblastic leukemia. [1] [2] It is a CD19-directed genetically modified autologous T-cell immunotherapy.
In 2011, a year after treatment, two of the three people with advanced chronic lymphocytic leukemia were reported to be cancer-free [99] and in 2013, three of five subjects who had acute lymphocytic leukemia were reported to be in remission for five months to two years. [100]
Currently, standard treatment for T-cell acute lymphoblastic leukemia (T-ALL) involves long-term chemotherapy and medication to prevent or treat side effects associated with low white blood cell counts resulting from intensive chemotherapy regimens. The treatment typically occurs in three stages: induction, consolidation, and maintenance. [3]
Tisagenlecleucel is indicated for the treatment of those under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse; or adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma ...
Numerous clinical studies have been conducted to evaluate the efficacy and safety of Erwinase in the treatment of acute lymphoblastic leukemia. One of the primary concerns in acute lymphoblastic leukemia treatment is the occurrence of adverse events (AEs) associated with asparaginase therapy.
Ads
related to: lymphoblastic leukemia treatment